TUBULIS
Tubulis develops chemotherapeutic medications to combat cancer and chronic disorders. The company's chemotherapeutic medications are specifically matched protein-drug conjugates created by merging proprietary innovative technology with disease-specific biology, allowing clinicians to treat cancer patients without the risks associated with chemotherapy.
TUBULIS
Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.tubulis.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
200 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon WordPress Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin Person Schema Facebook Sharer
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tesu Health
Tesu Health offers digital therapeutics for chronic diseases, focusing on non-chemical, non-biological treatments.
Current Advisors List
Current Employees Featured
Founder
Investors List
coparion
coparion investment in Series B - Tubulis
OCCIDENT
OCCIDENT investment in Series B - Tubulis
Evotec
Evotec investment in Series B - Tubulis
BioMedPartners
BioMedPartners investment in Series B - Tubulis
Bayern Kapital
Bayern Kapital investment in Series B - Tubulis
Frazier Life Sciences
Frazier Life Sciences investment in Series B - Tubulis
Fund+
Fund+ investment in Series B - Tubulis
Seventure Partners
Seventure Partners investment in Series B - Tubulis
Nextech Invest
Nextech Invest investment in Series B - Tubulis
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Series B - Tubulis
Key Employee Changes
| Date | New article |
|---|---|
| 2023-02-16 | Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer |
Official Site Inspections
http://www.tubulis.com Semrush global rank: 3.11 M Semrush visits lastest month: 4.93 K
- Host name: dd40828.kasserver.com
- IP address: 85.13.131.146
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Tubulis"
Meet the Team behind Tubulis - Tubulis
We are supported by a strong scientific and entrepreneurial network Together, the team has built a strong collaborative network bringing together expertise in chemistry, antibody technologies, …See details»
Tubulis - Crunchbase Company Profile & Funding
Organization. Tubulis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic …See details»
Tubulis - Overview, News & Similar companies | ZoomInfo.com
Feb 16, 2023 Who is Tubulis. Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic …See details»
Tubulis Company Profile 2024: Valuation, Funding & Investors
Tubulis General Information Description. Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. The company's chemotherapeutic drugs are uniquely …See details»
Tubulis - EQT Group
Nov 18, 2024 tubulis.com. Sector. Healthcare. Country. Germany. Fund. LSP 7. Entry. 2024. Web. tubulis.com. Latest news. 22 November 2024 EQT Exeter To Acquire More Than One …See details»
Tubulis Company Profile - Office Locations, Competitors ... - Craft
Tubulis has 5 employees at their 1 location and $13.72 m in total funding,. See insights on Tubulis including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Tubulis - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Tubulis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
Tubulis - Funding, Financials, Valuation & Investors - Crunchbase
Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Tubulis Technologies - VentureRadar
"Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of …See details»
First Phase I/IIa Patient Trial with ADC TUB-040 - Tubulis
Jun 20, 2024 About Tubulis Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic …See details»
Olivier Marcq - Tubulis | BioProcess International Europe Speaker
The mission: to create a CMC organization supporting the in-house grown pipeline based on Tubulis proprietary conjugation and linker payload technologies. Tubulis will count two active …See details»
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical ...
MUNICH, Germany, March 14, 2024--Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was …See details»
EQT Life Sciences Leads Tubulis’ Upsized €128 Million ... - EQT Group
Mar 14, 2024 Amsterdam, Netherlands, March 14, 2024 – EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Tubulis, which is developing a pipeline of …See details»
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi …
Dec 2, 2020 "We are honored that Tubulis selected our organization to help bring this novel therapeutic towards the clinic with the goal of benefiting patients worldwide," commented Dr. …See details»
Tubulis Forms Strategic Partnership with Wu
Dec 2, 2020 Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation WuXi Biologics and …See details»
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi …
Dec 2, 2020 - WuXi Biologics and WuXi STA to become Contract Development and Manufacturing Organization (CDMO) partners for Tubulis. MUNICH and SHANGHAI, Dec. 2, …See details»
Tubulis Receives FDA Fast Track Designation for Antibody-Drug …
Jun 27, 2024 For Tubulis Dominik Schumacher, CEO & Co-Founder Phone: +49 175 800 5594 Email: [email protected] Media Requests for Tubulis Trophic Communications Stephanie …See details»
Enabling durable treatment options in oncology - Tubulis
Tubulis’ antibody-drug conjugate (ADC) candidate TUB-030 is directed against 5T4, a cancer-associated antigen expressed in a wide range of solid tumor indications. It consists of an IgG1 …See details»
Tubulis Forms Strategic Partnership with WuXi STA and WuXi …
Dec 2, 2020 WuXi STA and WuXi Biologics to become Contract Development and Manufacturing Organization (CDMO) partners for Tubulis. MUNICH, GERMANY and …See details»